Skip to content
naulon
Not checkedNot checked for notices yet.

Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity

Qinglian Zhai, Maaike van der Lee, Teun van Gelder and 1 more

Frontiers in Pharmacology · 2022

doi:10.3389/fphar.2022.912618 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Cytochrome P450 3A (CYP3A) subfamily enzymes are involved in the metabolism of 40% of drugs in clinical use. Twin studies have indicated that 66% of the variability in CYP3A4 activity is hereditary. Yet, the complexity of the CYP3A locus and the lack of distinct drug metabolizer phenotypes has limited the identification and clinical application of CYP3A genetic variants compared to other Cytochrome P450 enzymes. In recent years evidence has emerged indicating that a substantial part of the missing heritability is caused by low frequency genetic variation. In this review, we outline the current pharmacogenomics knowledge of CYP3A activity and discuss potential future directions to improve our genetic knowledge and ability to explain CYP3A variability.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.